You are here

Our science / Clinical Trials / Find a Trial / NCT01304641

Cardiovascular Events Based On Statin Initiation In The Elderly

Back to Search Print Save as PDF Bookmark Trial

NCT01304641

Last updated on May 10, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Cardiovascular, Dyslipidemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
65+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- ≥ 1 fill for atorvastatin or simvastatin (not including combination therapy) between
01 July 2006 and 30 November 2008

- Age ≥ 65 years as of the year of index date

- Continuous enrollment with medical and pharmacy benefits during the analytic period

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- 1 or more fills for a statin or other dyslipidemia medication in the 12-month
pre-index period

- A pharmacy fill for clopidogrel or nitrates (except concomitant hydralazine) in the
12-month pre-index period

- Patients with evidence of a cardiovascular event in the 12-month pre-index period.

- Patients who received both atorvastatin and simvastatin on the index date

- Patients with unknown gender or region

- Patients who received dyslipidemia medications other than the index drug within 1
months (30 days) following the index date

NCT01304641
Pfizer
Completed
Cardiovascular Events Based On Statin Initiation In The Elderly

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Hypercholesterolemia, Dyslipidemia
Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin
NCT01163851
All Genders
18+
Years
Multiple Sites
Hypertension and Cardiovascular Risk Factors
Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors
NCT00579254
All Genders
Primary Hyperlipidemia or Mixed Dyslipidemia
Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects
NCT02947334
All Genders
18+
Years
Beijing, Beijing
Hypercholesterolemia, Dyslipidemias, Hyperlipidemias, Lipid Metabolism Disorders, Metabolic Diseases
A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 in Subjects With Hypercholesterolemia
NCT01435382
All Genders
18+
Years
Multiple Sites
Cardiovascular Events Based On Statin Initiation In The Elderly
Comparison Of Cardiovascular Event Rates In Elderly Patients With Newly Initiated Atorvastatin Or Simvastatin
The purpose of this study is to compare rates and risk of primary cardiovascular events among elderly patients newly initiating therapy with atorvastatin or simvastatin. The specific objectives for this project are to: 1) examine the demographic and clinical characteristics of the elderly patients in whom atorvastatin or simvastatin was newly initiated; and 2) compare cardiovascular event rates in elderly patients in whom atorvastatin or simvastatin was newly initiated.
All subjects meeting sample definition, all inclusion criteria, and none of the exclusion criteria.
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
This study included commercial health plan members and Medicare Advantage Part D enrollees ages 65 years and older with a prescription for atorvastatin or simvastatin filled between 01 July 2006 and 30 November 2008 (subject identification period). The first observed atorvastatin or simvastatin fill during the subject identification period was defined as the index drug and the fill date was defined as the index date. A 12-month period prior to the index date (defined as the pre-index period) was used for identification of comorbid exclusionary conditions. The 12-month period prior to index date was also used for assessment of pre-index patient characteristics. Patients were observed for a minimum of 3 months (following index date) until the earlier of either 1) disenrollment from the health plan or 2) 28 February 2009 (post-index period). The pre- and post-index periods in combination were defined as the analytic period.
  • Cardiovascular
  • Dyslipidemia
  • Other: Atorvastatin Initiators
    Retrospective database analysis no intervention performed.
  • Other: Simvastatin Initiators
    Retrospective database analysis no intervention performed.
  • Atorvastatin Initiators
    Intervention: Other: Atorvastatin Initiators
  • Simvastatin Initiators
    Intervention: Other: Simvastatin Initiators
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
31603
February 2011
February 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • ? 1 fill for atorvastatin or simvastatin (not including combination therapy) between 01 July 2006 and 30 November 2008
  • Age ? 65 years as of the year of index date
  • Continuous enrollment with medical and pharmacy benefits during the analytic period

Exclusion Criteria:

  • 1 or more fills for a statin or other dyslipidemia medication in the 12-month pre-index period
  • A pharmacy fill for clopidogrel or nitrates (except concomitant hydralazine) in the 12-month pre-index period
  • Patients with evidence of a cardiovascular event in the 12-month pre-index period.
  • Patients who received both atorvastatin and simvastatin on the index date
  • Patients with unknown gender or region
  • Patients who received dyslipidemia medications other than the index drug within 1 months (30 days) following the index date
Sexes Eligible for Study: All
65 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01304641
A2581188
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
March 2012

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now